IBDEI0M3 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10479,0)
 ;;=190.4^^44^565^40
 ;;^UTILITY(U,$J,358.3,10479,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10479,1,3,0)
 ;;=3^Cornea Malig Neopl
 ;;^UTILITY(U,$J,358.3,10479,1,4,0)
 ;;=4^190.4
 ;;^UTILITY(U,$J,358.3,10479,2)
 ;;=^267275
 ;;^UTILITY(U,$J,358.3,10480,0)
 ;;=V67.09^^44^566^22
 ;;^UTILITY(U,$J,358.3,10480,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10480,1,3,0)
 ;;=3^F/U Vitreous Surgery
 ;;^UTILITY(U,$J,358.3,10480,1,4,0)
 ;;=4^V67.09
 ;;^UTILITY(U,$J,358.3,10480,2)
 ;;=F/U Vitreous Surgery^322080^V45.69^V43.1
 ;;^UTILITY(U,$J,358.3,10481,0)
 ;;=367.4^^44^566^44
 ;;^UTILITY(U,$J,358.3,10481,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10481,1,3,0)
 ;;=3^Presbyopia
 ;;^UTILITY(U,$J,358.3,10481,1,4,0)
 ;;=4^367.4
 ;;^UTILITY(U,$J,358.3,10481,2)
 ;;=Presbyopia^98095
 ;;^UTILITY(U,$J,358.3,10482,0)
 ;;=379.21^^44^566^43
 ;;^UTILITY(U,$J,358.3,10482,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10482,1,3,0)
 ;;=3^Posterior Vitreous Detachment
 ;;^UTILITY(U,$J,358.3,10482,1,4,0)
 ;;=4^379.21
 ;;^UTILITY(U,$J,358.3,10482,2)
 ;;=^269309
 ;;^UTILITY(U,$J,358.3,10483,0)
 ;;=374.10^^44^566^20
 ;;^UTILITY(U,$J,358.3,10483,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10483,1,3,0)
 ;;=3^Ectropion
 ;;^UTILITY(U,$J,358.3,10483,1,4,0)
 ;;=4^374.10
 ;;^UTILITY(U,$J,358.3,10483,2)
 ;;=Ectropion^38326
 ;;^UTILITY(U,$J,358.3,10484,0)
 ;;=373.00^^44^566^8
 ;;^UTILITY(U,$J,358.3,10484,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10484,1,3,0)
 ;;=3^Blepharitis
 ;;^UTILITY(U,$J,358.3,10484,1,4,0)
 ;;=4^373.00
 ;;^UTILITY(U,$J,358.3,10484,2)
 ;;=Blepharitis^15271
 ;;^UTILITY(U,$J,358.3,10485,0)
 ;;=250.00^^44^566^13
 ;;^UTILITY(U,$J,358.3,10485,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10485,1,3,0)
 ;;=3^DM II w/o Eye Disease
 ;;^UTILITY(U,$J,358.3,10485,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,10485,2)
 ;;=DM Type II w/o Eye Disease^33605
 ;;^UTILITY(U,$J,358.3,10486,0)
 ;;=250.50^^44^566^12
 ;;^UTILITY(U,$J,358.3,10486,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10486,1,3,0)
 ;;=3^DM II w/PDR
 ;;^UTILITY(U,$J,358.3,10486,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,10486,2)
 ;;=DM II w/PDR^267839^362.02
 ;;^UTILITY(U,$J,358.3,10487,0)
 ;;=375.15^^44^566^19
 ;;^UTILITY(U,$J,358.3,10487,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10487,1,3,0)
 ;;=3^Dry Eye Syndrome
 ;;^UTILITY(U,$J,358.3,10487,1,4,0)
 ;;=4^375.15
 ;;^UTILITY(U,$J,358.3,10487,2)
 ;;=Dry Eye Syndrome^37168
 ;;^UTILITY(U,$J,358.3,10488,0)
 ;;=368.40^^44^566^50
 ;;^UTILITY(U,$J,358.3,10488,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10488,1,3,0)
 ;;=3^Visual Field Defect,Unspec
 ;;^UTILITY(U,$J,358.3,10488,1,4,0)
 ;;=4^368.40
 ;;^UTILITY(U,$J,358.3,10488,2)
 ;;=Visual Field Defect^126859
 ;;^UTILITY(U,$J,358.3,10489,0)
 ;;=366.53^^44^566^3
 ;;^UTILITY(U,$J,358.3,10489,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10489,1,3,0)
 ;;=3^After Cataract Obscurring Vision
 ;;^UTILITY(U,$J,358.3,10489,1,4,0)
 ;;=4^366.53
 ;;^UTILITY(U,$J,358.3,10489,2)
 ;;=After Cataract Obscurring Vision^268823
 ;;^UTILITY(U,$J,358.3,10490,0)
 ;;=366.9^^44^566^10
 ;;^UTILITY(U,$J,358.3,10490,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10490,1,3,0)
 ;;=3^Cataract, Unspecified
 ;;^UTILITY(U,$J,358.3,10490,1,4,0)
 ;;=4^366.9
 ;;^UTILITY(U,$J,358.3,10490,2)
 ;;=Cataract, Unspecified^20266
 ;;^UTILITY(U,$J,358.3,10491,0)
 ;;=362.83^^44^566^35
 ;;^UTILITY(U,$J,358.3,10491,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10491,1,3,0)
 ;;=3^Macular Edema (CSME)
 ;;^UTILITY(U,$J,358.3,10491,1,4,0)
 ;;=4^362.83
 ;;^UTILITY(U,$J,358.3,10491,2)
 ;;=Macular Edema^89576
 ;;
 ;;$END ROU IBDEI0M3
